Cognitive efficiency is associated with endogenous cytokine levels in patients with chronic hepatitis C

Journal of Neuroimmunology

Volumn 221, Issue 1-2, 2010, Pages 53-61

  Hilsabeck, Robin C ^a,b   Anstead, Gregory M ^a,c   Webb, Amy L ^a,c   Hoyumpa, Anastasio ^c   Ingmundson, Paul ^a   Holliday, Steve ^a,b   Zhang, Qiong ^a   Casas, Angela M ^a   Jovel, Marci ^a   Stern, Stephen L ^a,b  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

ANAM; Cognitive dysfunction; Cytokines; Hepatitis C; Immune system; Interferon

Indexed keywords

ALPHA INTERFERON; CYTOKINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; COGNITION; COGNITIVE DEFECT; FEMALE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; VETERAN; BLOOD; NEUROPSYCHOLOGICAL TEST; STATISTICS;

COGNITION DISORDERS; CYTOKINES; FEMALE; HEPATITIS C, CHRONIC; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; STATISTICS AS TOPIC;

EID: 77951234312     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2010.01.017     Document Type: Article

References (94)

1. Akwa Y., Hassett D.E., Eloranta M.L., Sandberg K., Masliah E., Powell H.C., Whitton J.L., Bloom F.E., Campbell I.L. Transgenic expression of IFN-alpha in the central nervous system of mice protects against lethal neurotropic viral infection but induces inflammation and neurodegeneration. J. Immun. 1998, 161:5016-5026.
2. Anisman H., Poulter M.O., Gandhi R., Merali Z., Hayley S.L. Interferon-α effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone, and brain monoamine variations. J. Neuroimmunol. 2007, 186:45-53.
3. Batteux F., Palmer P., Daëron M., Weill B., Lebon P. FCγRII (CD32)-dependent induction of interferon-alpha by serum from patients with lupus erythematosus. Eur. Cytokine Network 1999, 10:509-514.
4. Baune B.T., Ponath G., Golledge J., Varga G., Arolt V., Rothermundt M., Berger K. Association between IL-8 cytokine and cognitive performance in an elderly general population-the MEMO-Study. Neurobiol. Aging 2008, 29:937-944.
5. Bermejo P., Martin-Aragon S., Benedi J., Susin C., Felici E., Gil P., Ribera J.M., Villar A.M. Differences of peripheral inflammatory markers between mild cognitive impairment and Alzheimer's disease. Immunol. Lett. 2008, 117:198-202.
6. Bower W.A., Culver D.H., Castor D., Wu Y., James V.N., Zheng H., Hammer S., Kuhnert W.L., Williams I.T., Bell B.P., Vlahov D., Dezzutti C.S. Changes in hepatitis C virus (HCV) viral load and interferon-alpha levels in HIV/HCV-coinfected patients treated with highly active antiretroviral therapy. JAIDS 2006, 42:293-297.
7. Cacciarelli T.V., Martinez O.M., Gish R.G., Villanueva J.C., Krams S.M. Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa. Hepatology 1996, 24:6-9.
8. Calvert M., Gresser I. Interferon enhances the excitability of cultured neurons. Nature 1979, 278:558-560.
9. Campbell I.L., Krucker T., Steffensen S., Akwa Y., Powell H.C., Lane T., Carr D.J., Gold L.H., Henriksen S.J., Siggins G.R. Structural and functional neuropathology in transgenic mice with CNS expression of IFN-α. Brain Res. 1999, 835:46-61.
10. Capuron L., Pagnoni G., Demetrashvili M., Woolwine B.J., Nemeroff C.B., Berns G.S., Miller A.H. Anterior cingulate activation and error processing during interferon-alpha treatment. Biol. Psychiatry 2005, 58:190-196.
11. Castellano-Higuera A., Gonzalez-Reimers E., Aleman-Valls M.R., Abreu-Gonzalez P., Santolaria-Fernandez F., De La Vega-Prieto M.J., Gomez-Sirvent J.L., Pelazas-Gonzalez R. Cytokines and lipid peroxidation in alcoholics with chronic hepatitis C virus infection. Alcohol Alcohol. 2008, 43:137-142.
12. Chen T.Y., Hsieh Y.S., Wu T.T., Yang S.F., Wu C.J., Tsay G.J., Chiou H.L. Impact of serum levels and gene polymorphism of cytokines on chronic hepatitis C infection. Transl. Res.: J. Lab. Clin. Med. 2007, 150:116-121.
13. Chen J., Buchanan J.B., Sparkman N.L., Godbout J.P., Freund G.G., Johnson R.W. Neuroinflammation and disruption in working memory in aged mice after acute stimulation of the peripheral innate immune system. Brain Behav. Immun. 2008, 22:301-311.
14. Cribier B., Schmitt C., Rey D., Lang J.M., Kirn A., Stoll-Keller F. Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV. Res. Virol. 1996, 147:263-266.
15. Crow Y.J., Jackson A.P., Roberts E., van Beusekom E., Barth P., Corry P., Ferrie C.D., Hamel B.C., Jayatunga R., Karbani G., Kalmanchey R., Kelemen A., King M., Kumar R., Livingstone J., Massey R., McWilliam R., Meager A., Rittey C., Stephenson J.B., Tolmie J.L., Verrips A., Voit T., van Bokhoven H., Brunner H.G., Woods C.G. Aicardi-Goutières syndrome displays genetic heterogeneity with one locus (AGS1) on chromosome 3p21. Am. J. Hum. Genet. 2000, 67:213-221.
16. Crow Y.J., Black D.N., Ali M., Bond J., Jackson A.P., Lefson M., Michaud J., Roberts E., Stephenson J.B., Woods C.G., Lebon P. Cree encephalitis is allelic with Aicardi-Goutières syndrome: implications for the pathogenesis of disorders of interferon alpha metabolism. J. Med. Genetics 2003, 40:183-187.
17. Dafny N., Prieto-Gomez B., Dong W.Q., Reyes-Vazquez C. Interferon modulates neuronal activity recorded from the hypothalamus, thalamus, hippocampus, amygdala and the somatosensory cortex. Brain Res. 1996, 734:269-274.
18. Dieperink E., Willenbring M., Ho S.B. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am. J. Psychiatry 2000, 157:867-876.
19. Dik M.G., Jonker C., Hack C.E., Smit J.H., Comijs H.C., Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology 2005, 64:1371-1377.
20. Dinarello C.A., Bernheim H.A., Duff G.W., Le H.V., Nagabhushan T.L., Hamilton N.C., Coceani F. Mechanisms of fever induced by recombinant human interferon. J. Clin. Invest. 1984, 74:906-913.
21. Falasca K., Ucciferri C., Dalessandro M., Zingariello P., Mancino P., Petrarca C., Pizzigallo E., Conti P., Vecchiet J. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann. Clin. Lab. Sci. 2006, 36:144-150.
22. Fentiman I.S., Thomas B.S., Balkwill F.R., Rubens R.D., Hayward J.L. Primary hypothyroidism associated with interferon therapy of breast cancer. Lancet 1985, 1:1166.
23. Fontana R.J., Bieliauskas L.A., Back-Madruga C., Lindsay K.L., Kronfol Z., Lok A.S., Padmanabhan L. Cognitive function in hepatitis C patients with advanced fibrosis enrolled in the HALT-C trial. J. Hepatol. 2005, 43:614-622. the HALT-C Trial Group.
24. Forton D.M., Allsop J.M., Main J., Foster G.R., Thomas H.C., Taylor-Robinson S.D. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001, 358:38-39.
25. Forton D.M., Thomas H.C., Murphy C.A., Allsop J.M., Foster G.R., Main J., Wesnes K.A., Taylor-Robinson S.D. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002, 35:433-439.
26. Goutières F., Aicardi J., Barth P.G., Lebon P. Aicardi-Goutières Syndrome: an update and results of interferon-α studies. Ann. Neurology 1998, 44:900-907.
27. Hilsabeck R.C., Perry W., Hassassein T.I. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002, 35:440-446.
28. Hilsabeck R.C., Hassanein T.I., Carlson M.D., Ziegler E.A., Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J. Int. Neuropsychol. Soc. 2003, 9:847-854.
29. Hilsabeck R.C., Hassanein T.I., Ziegler E.A., Carlson M.D., Perry W. Effect of interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J. Int. Neuropsychol. Soc. 2005, 11:16-22.
30. Holliday S.L., Navarrete M.G., Hermosillo-Romo D., Valdez C.R., Saklad A.R., Escalante A., Brey R.L. Validating a computerized neuropsychological test battery for mixed ethnic lupus patients. Lupus 2003, 12:697-703.
31. Hooks J.J., Moutsopoulos H.M., Geis S.A., Stahl N.I., Decker J.L., Notkins A.L. Immune interferon in the circulation of patients with autoimmune disease. N. Eng. J. Med. 1979, 301:5-8.
32. Huckans M., Seelye A., Parcel T., Mull L., Woodhouse J., Bjornson D., Fuller B.E., Loftis J.M., Morasco B.J., Sasaki A.W., Storzbach D., Hauser P. The cognitive effects of hepatitis C in the presence and absence of a history of substance use disorder. JINS 2009, 15:69-82.
33. Isshi K., Hirohata S., Hashimoto T., Miyashita H. Systemic lupus erythematosus presenting with diffuse low density lesions in the cerebral white matter on computed axial tomography scans: its implication in the pathogenesis of diffuse central nervous system lupus. J. Rheumatol. 1994, 21:1758-1762.
34. Jankowsky J.L., Patterson P.H. Cytokine and growth factor involvement in long-term potentiation. Mol. Cell. Neurosci. 1999, 14:273-286.
35. Jones T.H., Wadler S., Hupart K.H. Endocrine-mediated mechanisms of fatigue during treatment with interferon-α. Semin. Oncol. 1998, 25:54-63.
36. Juengling F.D., Ebert D., Gut O., Engelbrecht M.A., Rasenack J., Nitzsche E.U., Bauer J., Lieb K. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology 2000, 152:383-389.
37. Kamei S., Tanaka N., Mastuura M., Arakawa Y., Kojima T., Matsukawa Y., Takasu T., Moriyama M. Blinded, prospective, and serial evaluation by quantitative-EEG in interferon-alpha-treated hepatitis-C. Acta Neurol. Scand. 1999, 100:25-33.
38. Kamei S., Sakai T., Matsuura M., Tanaka N., Kojima T., Arakawa Y., Matsukawa Y., Mizutani T., Oga K., Ohkubo H., Matsumura H., Hirayanagi K. Alterations of quantitative EEG and Mini-Mental State Examination in interferon-α-treated hepatitis C. Eur. Neurol. 2002, 48:102-107.
39. Kamei S., Oga K., Matsuura M., Tanaka N., Kojima T., Arakawa Y., Matsukawa Y., Mizutani T., Sakai T., Ohkubo H., Matsumura H., Moriyama M., Hirayanagi K. Correlation between quantitative-EEG alterations and age in patients with interferon-alpha-treated hepatitis C. J. Clin. Neurophys. 2005, 22:49-52.
40. Kane R.L., Roebuck-Spencer T., Short P., Kabat M., Wilken J. Identifying and monitoring cognitive deficits in clinical populations using Automated Neuropsychological Assessment Metrics (ANAM) tests. Arch. Clin. Neuropsychol. 2007, 22:S115-S126.
41. Kramer L., Bauer E., Funk G., Hofer H., Jessner W., Steindl-Munda P., Wrba F., Madl C., Gangl A., Ferenci P. Subclinical impairment of brain function in chronic hepatitis C infection. J. Hepatol. 2002, 37:349-354.
42. Kraus M.R., Schafer A., Wissmann S., Reimer P., Scheurlen M. Neurocognitive changes in patients with hepatitis C receiving interferon alfa-2b and ribavirin. Clin. Pharmacol. Ther. 2005, 77:90-100.
43. Krivine A., Force G., Servan J., Cabee A., Rozenberg F., Dighiero L., Marguet F., Lebon P. Measuring HIV-1 RNA and interferon-α in the cerebrospinal fluid or AIDS patients: insights into the pathogenesis of AIDS dementia complex. J. Neurovirol. 1999, 5:500-506.
44. Kronfol Z. Cytokines and Mental Health 2003, Kluwer Academic Publishers, Norwell, MA.
45. Lanzi G., Fazzi E., D'Arrigo S., Orcesi S., Maraucci I., Uggetti C., Bertini E., Lebon P. The natural history of Aicardi-Goutieres syndrome: follow-up of 11 Italian patients. Neurology 2005, 64:1621-1624.
46. Lau A.S., Der S.D., Read S.E., Williams B.R.G. Regulation of tumor necrosis factor receptor expression by acid-labile interferon-α from AIDS sera. AIDS Res. Hum. Retroviruses 1991, 7:545-552.
47. Lebon P., Lenoir G.R., Fischer A., Lagrue A. Synthesis of intrathecal interferon in systemic lupus erythematosus with neurological complications. Br. Med. J. Clin. Res. Ed. 1983, 287:1165-1167.
48. Lee S., Macquillan G.C., Keane N.M., Flexman J., Jeffrey G.P., French M.A., Brochier J., Price P. Immunological markers predicting outcome in patients with hepatitis C treated with interferon-alpha and ribavirin. Immunol. Cell Biol. 2002, 80:391-397.
49. Licinio J., Kling M.A., Hauser P. Cytokines and brain function: relevance to interferon-α-induced mood and cognitive changes. Semin. Oncol. 1998, 25:30-38.
50. Loftis J.M., Huckans M., Ruimy S., Hinrichs D.J., Hauser P. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci. Lett. 2008, 430:264-268.
51. Magaki S., Meuller C., Dickson C., Kirsch W. Increased production of inflammatory cytokines in mild cognitive impairment. Exp. Gerontol. 2007, 42:233-240.
52. Maier S.F. Bi-directional immune-brain communication: implications for understanding stress, pain, and cognition. Brain Behav. Immun. 2003, 17:69-85.
53. Majer M., Welberg L.A.M., Capuron L., Pagnoni G., Raison C.L., Miller A.H. IFN-alpha-induced motor slowing is associated with increased depression and fatigue in patients with chronic hepatitis C. Brain Behav. Immun. 2008, 22:870-880.
54. Marsland A.L., Petersen K.L., Sathanoori R., Muldoon M.F., Neumann S.A., Ryan C., Flory J.D., Manuck S.B. Interleukin-6 covaries inversely with cognitive performance among middle-aged community volunteers. Psychosom. Med. 2006, 68:895-903.
55. Mathur A., Choudhary H.R. Systemic lupus erythematosus causing cerebral infarction and basal ganglion calcification: a case report. Neurol. India 2000, 48:91.
56. McAfoose J., Baune B.T. Evidence for a cytokine model of cognitive function. Neurosci. Biobehav. Rev. 2009, 33:355-366.
57. McAndrews M.P., Farcnik K., Carlen P., Damyanovich A., Mrkonjic M., Jones S., Heathcote E.J. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005, 41:801-808.
58. Meyers C.A., Albitar M., Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005, 104:788-793.
59. Migita K., Abiru S., Maeda Y., Daikoku M., Ohata K., Nakamura M., Komori A., Yano K., Yatsuhashi H., Eguchi K., Ishibashi H. Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection. Hum. Immunol. 2006, 67:27-32.
60. Nelson D.R., Lim H.L., Marousis C.G., Fang J.W., Davis G.L., Shen L., Urdea M.S., Kolberg J.A., Lau J.Y. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig. Dis. Sci. 1997, 42:2487-2494.
61. Neuman M., Angulo P., Malkiewicz I., Jorgensen R., Shear N., Dickson E.R., Haber J., Katz G., Lindor K. Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis. J. Gastroenterol. Hepatol. 2002, 17:196-202.
62. Neuman M.G., Benhamou J.P., Marcellin P., Valla D., Malkiewicz I.M., Katz G.G., Trepo C., Bourliere M., Cameron R.G., Cohen L., Morgan M., Schmilovitz-Weiss H., Ben-Ari Z. Cytokine-chemokine and apoptotic signatures in patients with hepatitis C. Transl. Res.: J. Lab. Clin. Med. 2007, 149:126-136.
63. Pawelczyk T., Pawelczyk A., Strzelecki D., Rabe-Jablonska J. Pegylated interferon alpha and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients. Gen. Hos. Psychiatry 2008, 30:501-508.
64. Perrella O., Carrieri P.B., Perrella A., Sbreglia C., Gorga F., Guarnaccia D., Tarantino G. Transforming growth factor-beta1 and interferon-alpha in the AIDS dementia complex (ADC): possible relationship with cerebral viral load?. Eur. Cytokine Network 2001, 12:51-55.
65. Perry W., Hilsabeck R.C., Hassanein T.I. Cognitive dysfunction in chronic hepatitis C: a review. Dig. Dis. Sci. 2008, 53:307-321.
66. Petitto J.M., McNamara R.K., Gendreau P.L., Huang Z., Jackson A.J. Impaired learning and memory and altered hippocampal neurodevelopment resulting from interleukin-2 gene deletion. J. Neurosci. Res. 1999, 56:441-446.
67. Pike J.L., Irwin M.R. Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav. Immun. 2006, 20:169-174.
68. Radloff L.S. The CES-D scale: a self report depression scale for research in the general population. App. Psychol. Measurement 1977, 1:385-401.
69. Rafnsson S.B., Deary I.J., Smith F.B., Whiteman M.C., Rumley A., Lowe G.D., Fowkes F.G. Cognitive decline and markers of inflammation and hemostasis: the Edinburgh Artery Study. J. Am. Ger. Soc. 2007, 55:700-707.
70. Raison C.L., Borisov A.S., Majer M., Drake D.F., Pagnoni G., Woolwine B.J., Vogt G.J., Massung B., Miller A.H. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatry 2009, 65:296-303.
71. Raymond A.A., Zariah A.A., Samad S.A., Chin C.N., Kong N.C. Brain calcification in patients with cerebral lupus. Lupus 1996, 5:123-128.
72. Reeves D., Kane R., Winter K. ANAM V3.11a/96 user's manual: clinical and neurotoxicology subsets 1996, National Cognitive Recovery Foundation, San Diego, CA.
73. Reichenberg A., Yirmiya R., Schuld A., Kraus T., Haack M., Morag A., Pollmächer T. Cytokine-associated emotional and cognitive disturbances in humans. Arch. Gen. Psych. 2001, 58:445-452.
74. Rho M.B., Wesselingh S., Glass J.D., McArthur J.C., Choi S., Criffin J., Tyor W.R. A potential role for interferon-α in the pathogenesis of HIV-associated dementia. Brain Behav. Immun. 1995, 9:366-377.
75. Roebuck-Spencer T.M., Reeves D.L., Bleiberg J., Cernich A.N., Schwab K., Ivins B., Salazar A., Harvey S., Brown F., Warden D. Influence of demographics on computerized cognitive testing in a military sample. Mil. Psychol. 2009, 20:1-17.
76. Rönnblom L., Alm G.V. A pivotal role for the natural interferon-α producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus. J. Exp. Med. 2001, 194:F59-F63.
77. Sarder M., Abe K., Saito H., Nishiyama N. Comparative effect of IL-2 and IL-6 on morphology of cultured hippocampal neurons from fetal rat brain. Brain Res. 1996, 715:9-16.
78. Schram M.T., Euser S.M., de Craen A.J., Witteman J.C., Frolich M., Hofman A., Jolles J., Breteler M.M., Westendorp R.G. Systemic markers of inflammation and cognitive decline in old age. J. Am. Ger. Soc. 2007, 55:708-716.
79. Schultz M., Muller R., von zur Muhlen A., Brabant G. Induction of hyperthyroidism by interferon-alpha-2b. Lancet 1989, 1:1452.
80. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59:S22-S33.
81. Shimizu H., Ohtani K.I., Sato N., Nagamine T., Mori M. Increase in serum interleukin-6, plasma ACTH and serum cortisol levels after systemic interferon-α administration. Endocr. J. 1995, 42:551-556.
82. Shiozawa S., Kuroki Y., Kim M., Hirohata S., Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum. 1992, 35:417-422.
83. Siegel S.D., Antoni M.H., Fletcher M.A., Maher K., Segota M.C., Klimas N. Impaired natural immunity, cognitive dysfunction, and physical symptoms in patients with chronic fatigue syndrome: preliminary evidence for a subgroup?. J. Psychosom. Res. 2006, 60:559-566.
84. Verma V., Chakravarti A., Kar P. Cytokine levels of TGF-beta, IL-10, and sTNFalphaRII in type C chronic liver disease. Dig. Dis. Sci. 2008, 53:2233-2237.
85. Vial T., Choquet-Kastylevsky G., Liautard C., Descotes J. Endocrine and neurological adverse effects of the therapeutic interferons. Toxicology 2000, 142:161-172.
86. Weaver J.D., Huang M.H., Albert M., Harris T., Rowe J.W., Seeman T.E. Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging. Neurology 2002, 59:371-378.
87. Weissenborn K., Krause J., Bokemeyer M., Hecker H., Schuler A., Ennen J.C., Ahl B., Manns M.P., Boker K.W. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J. Hepatol. 2004, 41:845-851.
88. Wilken J.A., Sullivan C.L., Lewandowski A., Kane R.L. The use of ANAM to assess the side-effect profiles and efficacy of medication. Arch. Clin. Neuropsychol. 2007, 22:S127-S133.
89. Wilson C.J., Cohen H.J., Pieper C.F. Cross-linked fibrin degradation products (D-Dimer), plasma cytokines, and cognitive decline in community-dwelling elderly persons. J. Am. Ger. Soc. 2003, 51:1374-1381.
90. Wright H., Alex P., Nguyen T., Bader T., Gurakar A., Sebastian A., Gonzales L., Wallis G., Naylor M., Dozmorov I., Centola M., Nour B. Multiplex cytokine profiling of initial therapeutic response in patients with chronic hepatitis C virus infection. Dig. Dis. Sci. 2005, 50:1793-1803.
91. Wrona D. Neural-immune interactions: an integrative view of the bidirectional relationship between the brain and immune system. J. Neuroimmunol. 2006, 172:38-58.
92. Yaffe K., Lindquist K., Penninx B.W., Simonsick E.M., Pahor M., Kritchevsky S., Launer L., Kuller L., Rubin S., Harris T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 2003, 61:76-80.
93. Yamada T., Yamanaka I. Microglial localization of α-interferon receptor in human brain tissues. Neurosci. Lett. 1995, 189:73-76.
94. Yamada T., Horisberger M.A., Kawaguchi N., Moroo I., Toydoa T. Immunohistochemistry using antibodies to α-interferon and its induced protein, MxA, in Alzheimer's and Parkinson's disease brain tissues. Neurosci. Lett. 1994, 181:61-64.